Cresco Labs Inc. (CRLBF)
(Delayed Data from OTC)
$1.77 USD
-0.05 (-2.75%)
Updated Jun 7, 2024 04:00 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Brokerage Reports
Cresco Labs Inc. [CRLBF]
Reports for Purchase
Showing records 101 - 120 ( 129 total )
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Canada Update, Sales & Pricing Stabilizing
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Cannabis Sector Performance Analysis
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Industry-Wide Improvements but Guidance Revised Downwards for H2/22
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Start Spreading the Licenses New York, New York
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Assessing 2Q22 Cannabis Earnings
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
2Q22 In-Line, Brand Strong but Verticality Pressures 2H22, PT to $7
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Q222 In Line but Mgmt?s H222 Outlook Well Below Consensus and Our Estimates, Progress Towards Closing CCHW Acquisition Positive
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
EBITDA Slightly Above Expectations; Columbia Care Acquisition On-Track
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J
Company: Cresco Labs Inc.
Industry: Medical - Products
Cannabis Industry Update: 2Q22 Week II Earnings Preview
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
U.S. Cannabis 2Q22 Preview: Macro Impacting NT, Legislative Progess Warming
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Operating Income Gaining Investor Interest As Industry Matures
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
Weekly ReHash: Consumer Access Key - Opening More Retail Licenses
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
NJ Adult-Use Cannabis Update: New Recreational Stores Added to Begin Sales
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Cresco Labs Inc.
Industry: Medical - Products
Company: Cresco Labs Inc.
Industry: Medical - Products
1Q22 In-Line, Leveraging Brand Success Ahead of Acquisition Close
Provider: Roth Capital Partners, Inc.
Analyst: FORTUNE S
Company: Cresco Labs Inc.
Industry: Medical - Products
In Line Q122 Results Demonstrate Market Share Gains, Awaiting Details on Progress with Possible Divestitures
Provider: Echelon Welath Partners
Analyst: SEMPLE A
Company: Cresco Labs Inc.
Industry: Medical - Products
Revenue Above Expectations as Acquisition of Columbia Care Remains On-Track
Provider: VENTUM CAPITAL MARKETS
Analyst: ZANDBERG J